{"publication_id":"b642629d-7848-45dd-ae31-6947fe25f9e1","screening":{"identified":67,"screened":67,"excluded":0,"included":67,"included_or_retained":67,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"67 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that Taurine supplementation remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","13 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=3, null=6, positive=3. Directness coding: direct=2, indirect=1, review=10.","Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.","A second limitation is single-source dependence for several outcome classes that nevertheless appear in the synthesis. The Longevity class is supported only by Mottaghi 2026 (liver-transplant graft outcomes, direct but narrow); Mortality is supported by Stijn 2015 and Zhang 2024 alone; Safety/Comorbidity is supported only by Zinellu 2015 in chronic kidney disease; and the Deficiency/Prevalence class rests on Marcangeli 2025, a small biomarker study in men aged 20–100. Because each of these outcome classes is touched by one — or at most two — sources, the within-corpus replication that would normally anchor an evidence map is absent, and any effect direction for these classes should be treated as hypothesis-generating rather than confirmatory.","A fourth limitation is the narrow endpoint scope of the human evidence. Patient-important endpoints such as incident cardiovascular events, hospitalisation for heart failure, fragility fracture, or dementia incidence are not reported in any of the in-corpus RCTs, and the energy-drink literature (Basrai 2019, Acute Effects of Energy 2025) addresses acute pressor responses (P < 0.00001) rather than chronic vascular outcomes. To our reading, the balance of the human evidence suggests that taurine may have a role as an adjunct for specific cardiometabolic and exercise endpoints in selected populations, but does not constitute a standalone anti-aging therapy in humans, and the boundary conditions for that adjunct role remain to be established.","Across 67 curated reference papers, the evidence base for taurine shows a context-dependent profile. Positive signals appear in: contextual adjacent evidence, cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: contextual adjacent evidence, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The taurine anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}